Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Mary T. Scott(Blood Cancer UK), David Vetrie(University of Glasgow)
Cited by 132
Related Papers
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease
|Nature Communications|2024|15